TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03658486

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
Study: NCT02014636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
Study: NCT02487420

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: shorter or longer period of specific dietary restrictions
Description: step by step gradual introduction of egg containing food products

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: shorter or longer period of specific dietary restrictions
Description: step by step gradual introduction of egg containing food products
Study: NCT00336453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection
Study: NCT03928977

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
Study: NCT00336453

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.25mL dose for intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: 0.25mL dose for intramuscular injection
Study: NCT03233555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Have access to EXCELS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Have access to EXCELS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03233555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive quarterly calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive quarterly calls
Study: NCT01499277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: IV ceftaroline 600mg every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: IV vancomycin 15mg/kg every 12 hours
Study: NCT03009266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
Study: NCT00558870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.
Study: NCT02175732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'KnowIt'
Description: Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine.
Study: NCT01499277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: IV aztreonam 1 g every 8 hours
Study: NCT02175732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'OnTrack'
Description: Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine.
Study: NCT05193110

Intervention type: OTHER
Group type: OTHER
Intervention: Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis
Description: Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology

Intervention type: OTHER
Group type: OTHER
Intervention: Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis
Description: Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology
Study: NCT02364089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical removal of the adrenal tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized medical treatment of hypertension by SAHR
Description: Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day.
Study: NCT03456921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-of-life conversation game called Hello
Description: To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
Study: NCT04540042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelK2 (Part 1)
Description: I.V., multiple-dose (Day 1 and Day 22)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: I.V., multiple-dose (Day 1 and Day 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelK2 (Part 2)
Description: I.V., single-dose (Day 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: I.V., single-dose (Day 1)
Study: NCT03651284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aim2Be app with Live Coach + Fitbit + BMI tracking tools
Description: Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
Description: Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
Study: NCT02284282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal injection bupivacaine/morphine
Description: Spinal injection bupivacaine/morphine in laparoscopic surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: subcutaneum injection lidocaine
Description: placebo injection
Study: NCT04294719

Intervention type: OTHER
Intervention: Cognitive Adaptation Training (CAT)
Description: Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
Study: NCT00779376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine 300mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine 300mg tablets
Study: NCT01539590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB3
Description: Daily intravenous administration of 2 mg/kg BB3 for four (4) days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Study: NCT02639585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclinza and Sunvepra
Description: direct acting antiviral agent against to hepatitis C virus
Study: NCT01743911

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Sugar pills: 20mg orally, once a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil pills: 20mg orally, once a day for 2 weeks.
Study: NCT01849471

Intervention type: OTHER
Intervention: questionnaires
Description: patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
Study: NCT02788747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg elamipretide
Description: Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg elamipretide
Description: Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Study: NCT02054026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Study: NCT03659019

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
Study: NCT02649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roscovitine
Description: Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roscovitine
Description: Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
Study: NCT01967550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac diethylamine, DDEA 2.32% gel
Study: NCT00085735

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Craniospinal Irradiation
Description: Undergo craniospinal Irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roscovitine
Description: Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo treatment is lactose capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo treatment is lactose capsule.
Study: NCT00085735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo treatment is lactose capsule.
Study: NCT02969148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic bursectomy and D2 lymphadenectomy
Description: The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
Study: NCT00085735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02969148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 lymphadenectomy
Description: D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
Study: NCT03078140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Triferdine
Description: Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Triferdine/Ferli-6
Description: For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery.
Study: NCT03514810

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined Sertraline & Ketoprofen
Description: The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Combined Sertraline & Ketoprofen
Description: The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interleukins in MDD after treatment
Description: Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interleukins in MDD after treatment
Description: Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
Study: NCT03966339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
Study: NCT02206971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine analyses feedback
Description: biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
Study: NCT01701232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
Study: NCT02870478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
Study: NCT01967550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02247323

Intervention type: OTHER
Intervention: Risk of malignancy index
Description: Calculation of RMI before sugery.
Study: NCT01223703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study